Seil Sohn , M.D., Ph.D. 1 , 2 , 3 , 4 , Jinhee Kim , R.N., Ph.D., M.P.H. 5 , Chun Kee Chung , M.D., Ph.D. 1 , 2 , 3 , 6 , Na Rae Lee , B.S. 7 , Moon Jun Sohn , M.D., Ph.D. 8 , Sung Hwan Kim , M.D., Ph.D. 9
28 February 2017
This 2009–2011 nation-wide study of adult Koreans was aimed to provide characteristics, medical utilization states, and survival rates for newly diagnosed patients with primary nonmalignant and malignant spine tumors.
Data for patients with primary spine tumors were selected from the Korean Health Insurance Review and Assessment Service database. The data included their age, sex, health insurance type, co-morbidities, medical cost, and hospital stay duration. Hospital stay duration and medical costs per person occurring in one calendar year were used. In addition, survival rates of patients with primary malignant spine tumors were evaluated.
The incidence rate of a primary spine tumor increased with age, and the year of diagnosis ( p≤0.0001). Average annual medical costs ranged from 1627 USD (pelvis & sacrum & coccyx tumors) to 6601 USD (spinal cord tumor) for primary nonmalignant spine tumor and from 12137 USD (spinal meningomas) to 20825 USD (pelvis & sacrum & coccyx tumors) for a primary malignant spine tumor. Overall survival rates for those with a primary malignant spine tumor were 87.0%, 75.3%, and 70.6% at 3, 12, and 24 months, respectively. The Cox regression model results showed that male sex, medicare insurance were significantly positive factors affecting survival after a diagnosis of primary malignant spine tumor.